TNK Therapeutics
In May 2015 Sorrento announced that it has formed a wholly-owned subsidiary, TNK (pronounced as “tank”) Therapeutics, Inc. This subsidiary will focus on developing CAR.TNKs (Chimeric Antigen Receptor Tumor-attacking Neukoplast®) as well as other complementary cellular and immunotherapies targeting both solid tumors and hematological malignancies.

CAR.TNK’s holds tremendous potential for immunotherapeutic applications and maintains an excellent level of safety due to its short half-life and lack of IL-6 production. There are currently several prospective CAR.TNKs for development including indications for glioma, lung, breast, and pancreatic cancers.

Ark Animal Health

Resiniferatoxin (RTX), a non-opiate solution for intractable pain for both human and veterinary applications is being developed for animal companions through Sorrento’s 100% owned subsidiary, Ark Animal Health. Ark’s RTX based products target a large market with unmet needs. Indications for RTX for dogs include osteosarcoma, osteoarthritis, and cancer pain. Another RTX drug for dogs is also being developed to treat staphylococcus infections. Indications of RTX for horses involve the treatment of hoof problems that involve neuropathic pain, navicular syndrome, and laminitis.

Resiniferatoxin (RTX) is a naturally occurring chemical found in cactus-like Euphorbia plants, which originate in several African countries. It is an ultra-potent analog of capsaicin, the active ingredient in chili peppers. On the Scoville scale, RTX has a rating of 16 billion, over 100,000 times hotter than a habanero. RTX causes an ion channel response in the plasma membrane of the sensory neurons.

RTX provides permanent, clinically meaningful analgesia, by eliminating a very specific subset of the nervous system calledafferent neurons.. These afferent nerves become hyperactive in inflammatory pain states such as metastasized cancer, but have no effect on normal acute pain sensations or muscle function RTX’s effect on Transient Receptor potential vanilloid 1 (TRPV1) pathway and their expression on afferent nerves is well known and well documented in scientific publications.

Sorrento Biologics

Sorrento Biologics Inc. is a wholly-owned subsidiary of Sorrento Therapeutics and is responsible for the development of  biosimilar/biobetter products. Sorrento Biologics is advancing four late-stage clinical products towards commercialization, STI-001 (Erbitux biosimilar/Biobetter), STI-002 (Remicade biosimilar/biobetter), STI-003 (Simulect biosimilar/Biobetter) and STI-004 (Xolair Biosimilar) as well as developing a robust pipeline of future products.